Compass pathways plcCMPS.US Overview

US StockHealthcare

(No presentation for CMPS)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

CMPS Overall Performance

CMPS AI Analysis & Strategy

CMPS Recent Performance

0.28%

Compass pathways plc

0.81%

Avg of Sector

-1.14%

S&P500

CMPS PowerScanner

CMPS Key Information

CMPS Valuation Metrics

CMPS Earnings Table

CMPS Profile

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.